Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Syringe device Clear all
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

NCT05975021
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Istaroxime, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

NCT03461406
View directory record Official record
Conditions
Excessive Bleeding During Surgery
Interventions
Fibrin Sealant Grifols, EVICEL
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Up to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chicago, Illinois • Michigan Center, Michigan • Albany, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

NCT04585815
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
43
States / cities
Duarte, California • Encinitas, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

NCT04023552
View directory record Official record
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
TQJ230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
8,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
287
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

L-Menthol Injection as a Novel Technique During Colonoscopy

NCT02588248
View directory record Official record
Conditions
Colonic Polyps, Colon Cancer
Interventions
Peppermint Oil, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

NCT02354417
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Biological: ProHema-CB
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 4, 2026, 4:54 AM EDT
Not yet recruiting Not applicable Interventional

Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair

NCT06953635
View directory record Official record
Conditions
Hernia, Ventral, Pain Management
Interventions
Quadratus Lumborum (QL) Block, Placebo
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Not applicable Interventional Results available

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

NCT04764396
View directory record Official record
Conditions
Pancreas, Mass Lesion
Interventions
Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe), Saline
Combination Product · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

NCT02678988
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AI-1000 G2, PFS-NSD, Tocilizumab
Device · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)

NCT04575324
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Telemedicine Linkage Intervention
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 4, 2026, 4:54 AM EDT
Recruiting Phase 4 Interventional

Multi-Center PAMPA Study

NCT05004727
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05281523
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

NCT02057250
View directory record Official record
Conditions
RA
Interventions
Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS), Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery

NCT02656472
View directory record Official record
Conditions
Pediatric Cardiac Surgery, Complication of Extracorporeal Circulation
Interventions
Tranexamic acid, Epsilon Aminocaproic Acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
3 Months to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT01970475
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 501, Adalimumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Victorville, California • Jupiter, Florida • Sandy Springs, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Not applicable Interventional Results available

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

NCT02080312
View directory record Official record
Conditions
Meniere's Disease
Interventions
Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

NCT06307626
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

NCT06730555
View directory record Official record
Conditions
HIV Infections
Interventions
ACCESS Intervention, Control Group
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

NCT05989126
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
aflibercept 8 mg PFS
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Bellaire, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Tezepelumab Home Use Study

NCT03968978
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab (APFS), Tezepelumab (AI)
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 4, 2026, 4:54 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

NCT07602335
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, MCAM
Other · Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Recruiting Early Phase 1 Interventional

Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation

NCT07308808
View directory record Official record
Conditions
Spinal Cord Injuries (SCI), Neurogenic Bladder, Urinary Tract Infection (Diagnosis)
Interventions
Lactobacillus Crispatus, Saline bladder wash
Drug · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 4, 2026, 4:54 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

NCT07360301
View directory record Official record
Conditions
Well-Being, Psychological, Psychedelic Experiences
Interventions
Psilocybin, Saline Placebo, Clonidine
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 4, 2026, 4:54 AM EDT